Key Insights

Highlights

Success Rate

93% trial completion (above average)

Published Results

748 trials with published results (21%)

Research Maturity

2560 completed trials (71% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

5.2%

188 terminated out of 3595 trials

Success Rate

93.2%

+6.7% vs benchmark

Late-Stage Pipeline

27%

985 trials in Phase 3/4

Results Transparency

29%

748 of 2560 completed with results

Key Signals

748 with results93% success188 terminated

Data Visualizations

Phase Distribution

2,923Total
Not Applicable (1204)
Early P 1 (18)
P 1 (412)
P 2 (304)
P 3 (544)
P 4 (441)

Trial Status

Completed2,560
Unknown373
Recruiting219
Terminated188
Active Not Recruiting87
Withdrawn71

Trial Success Rate

93.2%

Benchmark: 86.5%

Based on 2560 completed trials

Clinical Trials (3595)

Showing 20 of 20 trials
NCT06489002Not ApplicableActive Not Recruiting

DEDICATE: aDvancing carE Management aDoption In Community heAlTh cEnters

NCT07415954Phase 2RecruitingPrimary

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

NCT01762046Phase 1CompletedPrimary

Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans

NCT07571590Not ApplicableNot Yet RecruitingPrimary

Effectiveness of a Self-Efficacy Based Educational Program on Glycemic Self-Monitoring, Diabetes Self-Management Knowledge, and Health-Related Quality of Life Among Adults With Type 2 Diabetes Mellitus

NCT04726319Not ApplicableCompleted

Family History App in Personalized Medicine

NCT07570992Phase 1Not Yet Recruiting

A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DM

NCT06209411Not ApplicableRecruitingPrimary

Community Health Worker-Led Postpartum Diabetes Screening

NCT06534411Phase 3Active Not RecruitingPrimary

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

NCT05427682Phase 1CompletedPrimary

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Pyroglutamate Rongliflozin Capsules in Subjects With Mild and Moderate Liver Damage

NCT05365438Phase 4Recruiting

Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

NCT05365425Phase 4Recruiting

Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

NCT05689372Enrolling By InvitationPrimary

Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

NCT04451980Completed

The HIV, Adipose Tissue Immunology, and Metabolism Study

NCT01878045Suspended

Mechanisms of Diabetic Kidney Disease in American Indians

NCT06907862Not ApplicableRecruiting

The SWITCH (Substitution of High With Low Ultra-processed Soy Protein Foods In a Guideline-based Diet inTervention for Cardiometabolic Health) Trial

NCT04953442Not ApplicableCompletedPrimary

Fit 24 Technology Intervention YOUTH

NCT04557228Not ApplicableCompletedPrimary

ADAM17 and Vascular Function in Diabetes

NCT03940209Phase 2CompletedPrimary

Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries

NCT06251323Not ApplicableRecruitingPrimary

Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)

NCT00340132Completed

Cross-Sectional and Longitudinal Studies of "Pre-Diabetes" in the Pima Indians

Scroll to load more

Research Network

Activity Timeline